The Biomarker Toolkit - an evidence-based guideline to predict cancer biomarker success and guide development.
Biomarkers
Breast cancer
Clinical utility
Colorectal cancer
Translational research
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
04 10 2023
04 10 2023
Historique:
received:
01
03
2023
accepted:
08
09
2023
medline:
2
11
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
An increased number of resources are allocated on cancer biomarker discovery, but very few of these biomarkers are clinically adopted. To bridge the gap between Biomarker discovery and clinical use, we aim to generate the Biomarker Toolkit, a tool designed to identify clinically promising biomarkers and promote successful biomarker translation. All features associated with a clinically useful biomarker were identified using mixed-methodology, including systematic literature search, semi-structured interviews, and an online two-stage Delphi-Survey. Validation of the checklist was achieved by independent systematic literature searches using keywords/subheadings related to clinically and non-clinically utilised breast and colorectal cancer biomarkers. Composite aggregated scores were generated for each selected publication based on the presence/absence of an attribute listed in the Biomarker Toolkit checklist. Systematic literature search identified 129 attributes associated with a clinically useful biomarker. These were grouped in four main categories including: rationale, clinical utility, analytical validity, and clinical validity. This checklist was subsequently developed using semi-structured interviews with biomarker experts (n=34); and 88.23% agreement was achieved regarding the identified attributes, via the Delphi survey (consensus level:75%, n=51). Quantitative validation was completed using clinically and non-clinically implemented breast and colorectal cancer biomarkers. Cox-regression analysis suggested that total score is a significant driver of biomarker success in both cancer types (BC: p>0.0001, 95.0% CI: 0.869-0.935, CRC: p>0.0001, 95.0% CI: 0.918-0.954). This novel study generated a validated checklist with literature-reported attributes linked with successful biomarker implementation. Ultimately, the application of this toolkit can be used to detect biomarkers with the highest clinical potential and shape how biomarker studies are designed/performed.
Sections du résumé
BACKGROUND
An increased number of resources are allocated on cancer biomarker discovery, but very few of these biomarkers are clinically adopted. To bridge the gap between Biomarker discovery and clinical use, we aim to generate the Biomarker Toolkit, a tool designed to identify clinically promising biomarkers and promote successful biomarker translation.
METHODS
All features associated with a clinically useful biomarker were identified using mixed-methodology, including systematic literature search, semi-structured interviews, and an online two-stage Delphi-Survey. Validation of the checklist was achieved by independent systematic literature searches using keywords/subheadings related to clinically and non-clinically utilised breast and colorectal cancer biomarkers. Composite aggregated scores were generated for each selected publication based on the presence/absence of an attribute listed in the Biomarker Toolkit checklist.
RESULTS
Systematic literature search identified 129 attributes associated with a clinically useful biomarker. These were grouped in four main categories including: rationale, clinical utility, analytical validity, and clinical validity. This checklist was subsequently developed using semi-structured interviews with biomarker experts (n=34); and 88.23% agreement was achieved regarding the identified attributes, via the Delphi survey (consensus level:75%, n=51). Quantitative validation was completed using clinically and non-clinically implemented breast and colorectal cancer biomarkers. Cox-regression analysis suggested that total score is a significant driver of biomarker success in both cancer types (BC: p>0.0001, 95.0% CI: 0.869-0.935, CRC: p>0.0001, 95.0% CI: 0.918-0.954).
CONCLUSIONS
This novel study generated a validated checklist with literature-reported attributes linked with successful biomarker implementation. Ultimately, the application of this toolkit can be used to detect biomarkers with the highest clinical potential and shape how biomarker studies are designed/performed.
Identifiants
pubmed: 37794461
doi: 10.1186/s12916-023-03075-3
pii: 10.1186/s12916-023-03075-3
pmc: PMC10552368
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
383Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
EJIFCC. 2018 Jul 11;29(2):129-137
pubmed: 30050396
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2095-2105
pubmed: 36215181
Fam Med Community Health. 2019 Mar 8;7(2):e000057
pubmed: 32148704
Clin Chem Lab Med. 2019 May 27;57(6):845-855
pubmed: 30412463
PLoS One. 2018 Jun 20;13(6):e0198606
pubmed: 29924873
Nephron Clin Pract. 2011;119(3):c255-60
pubmed: 21921637
Evid Based Nurs. 2016 Apr;19(2):34-5
pubmed: 26872777
Adv Exp Med Biol. 2015;867:9-26
pubmed: 26530357
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
Clin Pharmacol Ther. 2016 Feb;99(2):208-13
pubmed: 26378777
Eur J Cancer. 2017 Oct;84:325-334
pubmed: 28865260
BMC Med. 2012 Aug 09;10:87
pubmed: 22876833
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
BMJ Open. 2014 Dec 30;4(12):e006682
pubmed: 25550297
Proteomics Clin Appl. 2010 Dec;4(12):892-903
pubmed: 21137030
Clin Chem. 2017 May;63(5):963-972
pubmed: 28270433
SAGE Open Med. 2019 Jan 02;7:2050312118822927
pubmed: 30637106
Ann Intern Med. 2003 Jan 7;138(1):W1-12
pubmed: 12513067